Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Florence's Uffizi Gallery moves treasures to safety after cyberattack - 2Manual for Financial plan Agreeable PC
- 3Figure out How to Advance Space in Your Pre-assembled Home for Upgraded Usefulness
- 4German official report: Teen social media ban faces legal hurdles
- 5Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- 5 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- From Modesty to Administration: Self-improvement in Interactive abilities
- Tesla Stock Hasn’t Looked This Cheap in a While
- Allow Innovative Progressions To have a Tremendous Effect
- Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
- Shakira's 2026 'Las Mujeres Ya No Lloran' U.S. Tour: How to get tickets, prices, dates and more
- CVS forecasts 2026 profit above estimates on strong performance
- China and Pakistan issue five-point peace plan for Middle East
